

**Experiment Number:** 03039 - 02  
**Test Type:** CHRONIC  
**Route:** Dermal  
**Species/Strain:** MICE/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

Triclosan  
**CAS Number:** 3380-34-5

**Date Report Requested:** 12/04/2020  
**Time Report Requested:** 13:42:33  
**First Dose M/F:** 09/11/13 / 09/11/13  
**Lab:** NCTR

**NTP Study Number:** C03039B  
**Lock Date:** 12/18/2017  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.3\_002  
**PWG Approval Date:** 10/13/2017

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
------------------	--------------	--------------	--------------	--------------	--------------	--------------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>
<b>Early Deaths</b>						
<b>Accidentally Killed</b>	<b>1</b>					
<b>Moribund</b>	<b>10</b>	<b>18</b>	<b>11</b>	<b>14</b>	<b>18</b>	<b>16</b>
<b>Natural Death</b>	<b>1</b>		<b>2</b>	<b>3</b>	<b>1</b>	
<b>Survivors</b>						
<b>Moribund</b>	<b>1</b>		<b>1</b>		<b>1</b>	<b>1</b>
<b>Terminal Sacrifice</b>	<b>35</b>	<b>30</b>	<b>34</b>	<b>31</b>	<b>28</b>	<b>31</b>
<b>Animals Examined Microscopically</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>	<b>48</b>

## ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Gallbladder	(45)	(44)	(43)	(41)	(40)	(46)
Histiocytic Sarcoma						1 (2%)
Intestine Large, Cecum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma			1 (2%)			
Adenoma				1 (2%)		
Intestine Large, Colon	(48)	(48)	(46)	(46)	(48)	(48)
Adenocarcinoma			1 (2%)			
Lymphoma Malignant			1 (2%)			
Intestine Large, Rectum	(47)	(48)	(46)	(46)	(48)	(48)
Intestine Small, Duodenum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma	1 (2%)			1 (2%)		
Intestine Small, Ileum	(47)	(48)	(46)	(46)	(47)	(48)
Lymphoma Malignant	2 (4%)					1 (2%)
Intestine Small, Jejunum	(47)	(48)	(46)	(46)	(47)	(48)
Adenocarcinoma			1 (2%)	2 (4%)		1 (2%)
Adenoma						1 (2%)
Lymphoma Malignant				1 (2%)		
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma	4 (8%)	1 (2%)	2 (4%)	5 (10%)	4 (8%)	3 (6%)
Hepatoblastoma	2 (4%)	1 (2%)				1 (2%)
Hepatocellular Adenoma	9 (19%)	9 (19%)	11 (23%)	10 (21%)	14 (29%)	9 (19%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Hepatocellular Adenoma, Multiple	16 (33%)	21 (44%)	23 (48%)	16 (33%)	17 (35%)	17 (35%)
Hepatocellular Carcinoma	14 (29%)	11 (23%)	16 (33%)	24 (50%)	19 (40%)	21 (44%)
Hepatocellular Carcinoma, Multiple	1 (2%)	6 (13%)	4 (8%)	3 (6%)	6 (13%)	6 (13%)
Hepatocholangiocarcinoma					2 (4%)	
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant	1 (2%)	1 (2%)	2 (4%)	1 (2%)		
Mesentery	(2)	(1)	(3)	(1)	(5)	(2)
Hepatocholangiocarcinoma, Metastatic, Liver					1 (20%)	
Sarcoma	2 (100%)					
Pancreas	(48)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant			1 (2%)	1 (2%)		
Schwannoma Malignant		1 (2%)				
Stomach, Forestomach	(48)	(48)	(48)	(47)	(48)	(48)
Squamous Cell Carcinoma		1 (2%)				
Squamous Cell Papilloma			1 (2%)			
Stomach, Glandular	(48)	(48)	(46)	(46)	(48)	(48)
Adenoma	1 (2%)					
Tongue	(0)	(0)	(0)	(1)	(0)	(0)
<b>CARDIOVASCULAR SYSTEM</b>						
Blood Vessel	(48)	(48)	(47)	(48)	(48)	(48)
Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Lymphoma Malignant				1 (2%)		
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Hepatocholangiocarcinoma, Metastatic, Liver					2 (4%)	
Lymphoma Malignant				1 (2%)		
<b>ENDOCRINE SYSTEM</b>						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Adrenal Cortex	(47)	(48)	(48)	(47)	(47)	(48)
Hepatocarcinoma, Metastatic, Liver					1 (2%)	
Lymphoma Malignant				1 (2%)		
Subcapsular, Adenoma	2 (4%)	4 (8%)	1 (2%)	1 (2%)	3 (6%)	
Adrenal Medulla	(47)	(47)	(48)	(47)	(46)	(48)
Pheochromocytoma Benign						1 (2%)
Pheochromocytoma Malignant					1 (2%)	1 (2%)
Islets, Pancreatic	(48)	(48)	(48)	(47)	(48)	(47)
Adenoma	1 (2%)	1 (2%)				
Carcinoma						1 (2%)
Parathyroid Gland	(41)	(46)	(46)	(44)	(44)	(45)
Pituitary Gland	(48)	(46)	(46)	(47)	(46)	(45)
Thyroid Gland	(48)	(48)	(48)	(47)	(48)	(47)
Lymphoma Malignant				1 (2%)		
Follicular Cell, Carcinoma			1 (2%)			
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(0)	(0)	(0)	(2)	(0)
Hepatocarcinoma, Metastatic, Liver					1 (50%)	
<b>GENITAL SYSTEM</b>						
Epididymis	(48)	(48)	(48)	(48)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Lymphoma Malignant		1 (2%)	1 (2%)	1 (2%)		
Mast Cell Tumor Malignant		1 (2%)				
Fat Pad, Epididymal	(0)	(0)	(0)	(1)	(1)	(0)
Hepatocarcinoma, Metastatic, Liver					1 (100%)	
Preputial Gland	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant			1 (2%)			
Prostate	(48)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Hepatocarcinoma, Metastatic, Liver					1 (2%)	
Lymphoma Malignant			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Seminal Vesicle	(48)	(48)	(46)	(46)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Testes	(48)	(48)	(47)	(48)	(48)	(48)
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(48)	(48)	(48)	(47)	(48)	(48)
Hemangiosarcoma			1 (2%)		2 (4%)	
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant			2 (4%)			
Mast Cell Tumor Malignant			1 (2%)			
Lymph Node	(2)	(3)	(4)	(3)	(2)	(2)
Axillary, Lymphoma Malignant	1 (50%)			1 (33%)		
Brachial, Lymphoma Malignant				1 (33%)		
Inguinal, Lymphoma Malignant				1 (33%)		
Lumbar, Histiocytic Sarcoma					1 (50%)	
Lumbar, Lymphoma Malignant		1 (33%)	1 (25%)	1 (33%)		
Mediastinal, Lymphoma Malignant	1 (50%)		1 (25%)	1 (33%)	1 (50%)	
Pancreatic, Fibrous Histiocytoma						1 (50%)
Pancreatic, Histiocytic Sarcoma					1 (50%)	
Pancreatic, Lymphoma Malignant	1 (50%)		1 (25%)	1 (33%)		
Renal, Fibrous Histiocytoma						1 (50%)
Renal, Histiocytic Sarcoma					1 (50%)	1 (50%)
Renal, Lymphoma Malignant	1 (50%)		3 (75%)	2 (67%)	1 (50%)	
Lymph Node, Mandibular	(47)	(46)	(48)	(48)	(48)	(47)
Histiocytic Sarcoma					1 (2%)	
Lymphoma Malignant			1 (2%)	1 (2%)		
Neuroblastoma Malignant, Metastatic, Brain, Cerebrum					1 (2%)	
Lymph Node, Mesenteric	(48)	(48)	(47)	(47)	(48)	(47)
Fibrous Histiocytoma						1 (2%)
Hemangiosarcoma	1 (2%)		1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Histiocytic Sarcoma					1 (2%)	1 (2%)
Lymphoma Malignant	3 (6%)	1 (2%)	3 (6%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Spleen	(47)	(48)	(48)	(47)	(48)	(48)
Fibrous Histiocytoma						1 (2%)
Hemangiosarcoma	1 (2%)	4 (8%)	3 (6%)		4 (8%)	3 (6%)
Histiocytic Sarcoma					1 (2%)	1 (2%)
Lymphoma Malignant	2 (4%)	1 (2%)	4 (8%)	2 (4%)	1 (2%)	1 (2%)
Thymus	(46)	(44)	(46)	(43)	(44)	(48)
Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant				1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(1)	(2)	(0)	(2)	(2)	(0)
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Fibrous Histiocytoma		1 (2%)				
Lymphoma Malignant				1 (2%)		
Subcutaneous Tissue, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Subcutaneous Tissue, Fibrosarcoma		2 (4%)				1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma	1 (2%)					
Subcutaneous Tissue, Hemangiosarcoma			1 (2%)			1 (2%)
Subcutaneous Tissue, Lipoma					1 (2%)	
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(1)	(1)	(0)	(3)	(0)
Cranium, Sarcoma, Deep Invasion		1 (100%)				
Vertebra, Hepatocholangiocarcinoma, Metastatic, Liver					1 (33%)	
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma					1 (2%)	
Osteosarcoma		1 (2%)				
Skeletal Muscle	(0)	(2)	(1)	(0)	(4)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Fibrosarcoma, Deep Invasion		1 (50%)				
Hemangiosarcoma					2 (50%)	
Hepatocholangiocarcinoma, Metastatic, Liver					2 (50%)	
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Neuroblastoma Malignant					1 (2%)	
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Meninges, Sarcoma		1 (2%)				
Olfactory Lobe, Neuroblastoma Malignant					1 (2%)	
Nerve Trigeminal	(0)	(1)	(1)	(0)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Cervical	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Lumbar	(0)	(1)	(1)	(0)	(0)	(0)
Spinal Cord, Thoracic	(0)	(1)	(1)	(0)	(0)	(0)
<b>RESPIRATORY SYSTEM</b>						
Lung	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	5 (10%)	5 (10%)	5 (10%)	6 (13%)	2 (4%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)					
Alveolar/Bronchiolar Carcinoma	2 (4%)	5 (10%)	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple		1 (2%)				1 (2%)
Hemangiosarcoma					1 (2%)	
Hepatoblastoma, Metastatic, Liver		1 (2%)				
Hepatocellular Carcinoma, Metastatic, Liver	6 (13%)	6 (13%)	3 (6%)	6 (13%)	4 (8%)	6 (13%)
Hepatocholangiocarcinoma, Metastatic, Liver					2 (4%)	
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant			2 (4%)	1 (2%)		
Osteosarcoma, Metastatic, Bone, Femur		1 (2%)				
Sarcoma				1 (2%)		
Schwannoma Malignant, Metastatic, Salivary Glands		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
Bronchiole, Adenoma			1 (2%)			
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Neuroblastoma Malignant					1 (2%)	
Adventitia, Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Trachea	(48)	(48)	(48)	(47)	(48)	(48)
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(47)	(48)	(44)	(47)	(48)	(47)
Hepatocholangiocarcinoma, Metastatic, Liver					1 (2%)	
Lymphoma Malignant				1 (2%)		
Lids, Adenoma		1 (2%)				
Harderian Gland	(48)	(48)	(48)	(47)	(48)	(48)
Adenoma	1 (2%)	4 (8%)	4 (8%)	4 (9%)	6 (13%)	5 (10%)
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant				1 (2%)		
<b>URINARY SYSTEM</b>						
Kidney	(48)	(48)	(48)	(47)	(48)	(48)
Adenoma			2 (4%)			1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)		
Fibrous Histiocytoma						1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver					2 (4%)	
Histiocytic Sarcoma						1 (2%)
Lymphoma Malignant			2 (4%)	1 (2%)		
Urinary Bladder	(48)	(48)	(48)	(47)	(48)	(48)
Lymphoma Malignant			1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically



Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

---

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(48)	*(48)
Histiocytic Sarcoma					1 (2%)	1 (2%)
Lymphoma Malignant	3 (6%)	1 (2%)	4 (8%)	2 (4%)	1 (2%)	1 (2%)
Mast Cell Tumor Malignant		1 (2%)	1 (2%)			

---

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

---

B6C3F1 MICE MALE	Veh ctrlMale	Tri 1.25Male	Tri 2.7 Male	Untreat Male	Tri 5.8 Male	Tri 12.5Male
------------------	--------------	--------------	--------------	--------------	--------------	--------------

---

**Tumor Summary for Males**

Total Animals with Primary Neoplasms (b)	41	42	44	43	45	43
Total Primary Neoplasms	68	85	86	79	92	93
Total Animals with Benign Neoplasms	31	35	37	31	37	29
Total Benign Neoplasms	36	45	48	38	43	39
Total Animals with Malignant Neoplasms	25	31	26	32	33	35
Total Malignant Neoplasms	32	40	38	41	49	54
Total Animals with Metastatic Neoplasms	6	9	3	6	7	6
Total Metastatic Neoplasms	6	9	3	8	24	6
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
--------------------	----------------	----------------	----------------	----------------	----------------	----------------

## Disposition Summary

Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	11	17	17	14	8	10
Natural Death	1	1			3	2
Survivors						
Moribund	1	1		1		1
Terminal Sacrifice	35	29	31	33	37	35
Animals Examined Microscopically	48	48	48	48	48	48

## ALIMENTARY SYSTEM

Esophagus	(48)	(48)	(48)	(48)	(48)	(48)
Gallbladder	(45)	(46)	(44)	(47)	(45)	(44)
Lymphoma Malignant			1 (2%)	2 (4%)		
Intestine Large, Cecum	(47)	(48)	(48)	(48)	(45)	(46)
Hepatocarcinoma, Metastatic, Liver			1 (2%)			
Leiomyoma		1 (2%)				
Leiomyosarcoma					1 (2%)	
Lymphoma Malignant			1 (2%)	1 (2%)		
Intestine Large, Colon	(47)	(47)	(48)	(48)	(45)	(46)
Intestine Large, Rectum	(47)	(48)	(48)	(48)	(45)	(46)
Anus, Sarcoma		1 (2%)				
Intestine Small, Duodenum	(47)	(47)	(48)	(48)	(45)	(46)
Adenoma	1 (2%)					
Lymphoma Malignant	1 (2%)					
Intestine Small, Ileum	(47)	(48)	(48)	(48)	(45)	(46)
Lymphoma Malignant	2 (4%)			1 (2%)		1 (2%)
Intestine Small, Jejunum	(47)	(48)	(48)	(48)	(45)	(46)
Adenocarcinoma			1 (2%)			
Lymphoma Malignant	1 (2%)			1 (2%)	1 (2%)	
Liver	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma		1 (2%)		1 (2%)		
Hepatocellular Adenoma	12 (25%)	8 (17%)	9 (19%)	11 (23%)	9 (19%)	12 (25%)
Hepatocellular Adenoma, Multiple	5 (10%)	5 (10%)	8 (17%)	11 (23%)	9 (19%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Hepatocellular Carcinoma	10 (21%)	6 (13%)	8 (17%)	10 (21%)	6 (13%)	7 (15%)
Hepatocellular Carcinoma, Multiple			1 (2%)	2 (4%)	2 (4%)	
Hepatocholangiocarcinoma			1 (2%)		1 (2%)	
Histiocytic Sarcoma		3 (6%)	3 (6%)		1 (2%)	1 (2%)
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	3 (6%)	3 (6%)	5 (10%)	4 (8%)	1 (2%)	2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Mesentery	(7)	(4)	(11)	(14)	(8)	(6)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)				
Hepatocholangiocarcinoma, Metastatic, Liver			1 (9%)		1 (13%)	
Histiocytic Sarcoma			1 (9%)			
Lymphoma Malignant			1 (9%)	1 (7%)		
Pancreas	(48)	(48)	(48)	(48)	(48)	(48)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)			
Histiocytic Sarcoma		1 (2%)	2 (4%)		1 (2%)	
Lymphoma Malignant	4 (8%)	2 (4%)	3 (6%)	4 (8%)		3 (6%)
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Salivary Glands	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		2 (4%)	4 (8%)	2 (4%)	1 (2%)	3 (6%)
Stomach, Forestomach	(48)	(48)	(48)	(48)	(48)	(48)
Squamous Cell Carcinoma	1 (2%)					
Squamous Cell Papilloma		2 (4%)		1 (2%)		1 (2%)
Stomach, Glandular	(47)	(48)	(48)	(48)	(45)	(46)
Lymphoma Malignant			1 (2%)	1 (2%)		
Polyp Adenomatous		1 (2%)				
Tongue	(0)	(0)	(0)	(0)	(0)	(1)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		1 (2%)	1 (2%)			
Heart	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Leukemia Erythrocytic						1 (2%)
Lymphoma Malignant		2 (4%)	2 (4%)			
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma		1 (2%)				
Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)			
Histiocytic Sarcoma					1 (2%)	
Leukemia Granulocytic	1 (2%)					
Lymphoma Malignant	1 (2%)	2 (4%)	3 (6%)	1 (2%)		1 (2%)
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Subcapsular, Adenoma	1 (2%)			2 (4%)		
Adrenal Medulla	(48)	(48)	(48)	(47)	(48)	(48)
Pheochromocytoma Benign		1 (2%)		2 (4%)		
Pheochromocytoma Malignant		1 (2%)		1 (2%)		1 (2%)
Islets, Pancreatic	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma	1 (2%)					3 (6%)
Carcinoma	1 (2%)			1 (2%)		
Lymphoma Malignant						1 (2%)
Parathyroid Gland	(44)	(45)	(45)	(43)	(45)	(43)
Pituitary Gland	(47)	(47)	(47)	(47)	(46)	(46)
Lymphoma Malignant	1 (2%)	2 (4%)		1 (2%)		
Pars Distalis, Adenoma		1 (2%)	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Pars Intermedia, Adenoma						1 (2%)
Thyroid Gland	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant			1 (2%)			
Follicular Cell, Adenoma				2 (4%)		
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(3)	(2)	(1)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (33%)				
Hepatocholangiocarcinoma, Metastatic, Liver			1 (50%)			
Histiocytic Sarcoma			1 (50%)			
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(46)	(44)	(45)	(45)	(45)	(43)
Lymphoma Malignant			1 (2%)			
Fat Pad, Ovarian/parametrial	(0)	(0)	(1)	(0)	(0)	(0)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (100%)			
Ovary	(48)	(48)	(48)	(48)	(48)	(48)
Cystadenocarcinoma						1 (2%)
Cystadenoma	4 (8%)	5 (10%)	2 (4%)	1 (2%)	1 (2%)	
Granulosa Cell Tumor Benign			1 (2%)			
Granulosa Cell Tumor Malignant	1 (2%)					
Histiocytic Sarcoma		4 (8%)	2 (4%)		1 (2%)	
Luteoma		1 (2%)	1 (2%)	2 (4%)		
Lymphoma Malignant	1 (2%)	3 (6%)	3 (6%)	3 (6%)	1 (2%)	
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Uterus	(48)	(48)	(48)	(48)	(48)	(48)
Carcinoma				1 (2%)		
Hemangioma						1 (2%)
Hemangiosarcoma			1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)			
Histiocytic Sarcoma		3 (6%)	3 (6%)		1 (2%)	1 (2%)
Leiomyoma			1 (2%)			
Leiomyosarcoma		1 (2%)				
Lymphoma Malignant	1 (2%)	2 (4%)	2 (4%)	2 (4%)		
Polyp Stromal	4 (8%)	1 (2%)	3 (6%)	4 (8%)	1 (2%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Sarcoma Stromal	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Schwannoma Malignant				1 (2%)		
Endometrium, Adenocarcinoma	1 (2%)		1 (2%)	2 (4%)		
Endometrium, Adenoma				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(47)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma			1 (2%)			
Histiocytic Sarcoma			2 (4%)			
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	1 (2%)	2 (4%)	3 (6%)	2 (4%)		1 (2%)
Osteosarcoma			1 (2%)			
Lymph Node	(7)	(4)	(8)	(6)	(2)	(6)
Lymphoma Malignant				1 (17%)		
Axillary, Lymphoma Malignant	1 (14%)		2 (25%)	1 (17%)		
Axillary, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Bronchial, Lymphoma Malignant				1 (17%)		
Inguinal, Lymphoma Malignant				1 (17%)		
Lumbar, Histiocytic Sarcoma		2 (50%)	1 (13%)		1 (50%)	
Lumbar, Lymphoma Malignant	1 (14%)		4 (50%)	2 (33%)		2 (33%)
Lumbar, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver			1 (13%)			
Mediastinal, Histiocytic Sarcoma		1 (25%)	1 (13%)			
Mediastinal, Lymphoma Malignant	3 (43%)	2 (50%)	3 (38%)	2 (33%)		2 (33%)
Pancreatic, Histiocytic Sarcoma		1 (25%)				
Pancreatic, Lymphoma Malignant	3 (43%)		5 (63%)	3 (50%)		2 (33%)
Renal, Histiocytic Sarcoma		1 (25%)	1 (13%)		1 (50%)	
Renal, Lymphoma Malignant	3 (43%)		3 (38%)	2 (33%)		3 (50%)
Renal, Sarcoma, Metastatic, Uncertain Primary Site				1 (17%)		
Lymph Node, Mandibular	(47)	(48)	(48)	(48)	(48)	(47)
Histiocytic Sarcoma		1 (2%)	1 (2%)			
Leukemia Granulocytic					1 (2%)	
Lymphoma Malignant	3 (6%)	3 (6%)	4 (8%)	5 (10%)	1 (2%)	3 (6%)
Lymph Node, Mesenteric	(48)	(47)	(46)	(48)	(46)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Fibrous Histiocytoma	1 (2%)					
Histiocytic Sarcoma	1 (2%)	2 (4%)	3 (7%)		1 (2%)	
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	6 (13%)	4 (9%)	5 (11%)	6 (13%)	2 (4%)	6 (13%)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Spleen	(48)	(48)	(48)	(48)	(48)	(48)
Hemangiosarcoma	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)			
Histiocytic Sarcoma		2 (4%)	2 (4%)		1 (2%)	
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	6 (13%)	3 (6%)	5 (10%)	6 (13%)	1 (2%)	7 (15%)
Sarcoma Stromal, Metastatic, Uterus			1 (2%)			
Thymus	(47)	(46)	(48)	(48)	(48)	(48)
Histiocytic Sarcoma		1 (2%)	1 (2%)			
Lymphoma Malignant	2 (4%)	2 (4%)	4 (8%)	4 (8%)		3 (6%)
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(47)	(48)	(46)	(46)	(47)	(47)
Lymphoma Malignant			2 (4%)			
Skin	(48)	(48)	(48)	(48)	(48)	(48)
Basosquamous Tumor Malignant					1 (2%)	
Fibrous Histiocytoma	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Subcutaneous Tissue, Fibrosarcoma	1 (2%)		1 (2%)	1 (2%)		1 (2%)
Subcutaneous Tissue, Hemangioma			1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma				1 (2%)		
Subcutaneous Tissue, Liposarcoma			1 (2%)			
Subcutaneous Tissue, Osteoma						1 (2%)
Subcutaneous Tissue, Sarcoma		2 (4%)	1 (2%)			
Skin, Control	(48)	(48)	(48)	(48)	(48)	(48)
Subcutaneous Tissue, Fibrosarcoma				1 (2%)		
Skin, Site Of Application	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant		1 (2%)	2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(1)	(0)	(0)	(1)	(0)
Cranium, Osteosarcoma					1 (100%)	
Pelvis, Osteosarcoma		1 (100%)				
Bone, Femur	(48)	(48)	(48)	(48)	(48)	(48)
Osteosarcoma			1 (2%)			
Skeletal Muscle	(1)	(2)	(2)	(3)	(0)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (50%)				
Hepatocholangiocarcinoma, Metastatic, Liver			1 (50%)			
Myxosarcoma	1 (100%)					
Rhabdomyosarcoma				1 (33%)		
Sarcoma, Metastatic, Uncertain Primary Site				1 (33%)		
Sarcoma, Deep Invasion		1 (50%)				
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant	1 (2%)			2 (4%)		
Brain, Cerebellum	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant				1 (2%)		
Osteosarcoma, Metastatic, Bone					1 (2%)	
Brain, Cerebrum	(48)	(48)	(48)	(48)	(48)	(48)
Lymphoma Malignant				1 (2%)		
Nerve Trigeminal	(0)	(0)	(1)	(1)	(0)	(0)
Peripheral Nerve, Sciatic	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord	(0)	(0)	(0)	(1)	(0)	(0)
Sarcoma, Metastatic, Uncertain Primary Site				1 (100%)		
Spinal Cord, Cervical	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Lumbar	(0)	(0)	(1)	(1)	(0)	(0)
Spinal Cord, Thoracic	(0)	(0)	(1)	(1)	(0)	(0)
<b>RESPIRATORY SYSTEM</b>						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

## P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Lung	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar/Bronchiolar Adenoma	3 (6%)	4 (8%)	4 (8%)	3 (6%)	4 (8%)	1 (2%)
Alveolar/Bronchiolar Carcinoma		2 (4%)			2 (4%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	1 (2%)	3 (6%)	1 (2%)	2 (4%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)		1 (2%)	
Histiocytic Sarcoma		1 (2%)	2 (4%)			1 (2%)
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic					1 (2%)	
Lymphoma Malignant	2 (4%)	3 (6%)	4 (8%)	4 (8%)	1 (2%)	1 (2%)
Osteosarcoma, Metastatic, Bone		1 (2%)				
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Nose	(48)	(48)	(48)	(48)	(48)	(48)
Osteosarcoma, Metastatic, Bone, Femur			1 (2%)			
Trachea	(48)	(48)	(48)	(48)	(48)	(48)
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(47)	(46)	(48)	(48)	(45)	(46)
Lymphoma Malignant			1 (2%)			
Melanoma Malignant				1 (2%)		
Harderian Gland	(48)	(48)	(47)	(48)	(48)	(47)
Adenocarcinoma				2 (4%)		
Adenoma	12 (25%)	4 (8%)	2 (4%)	2 (4%)	4 (8%)	2 (4%)
Lymphoma Malignant			1 (2%)	1 (2%)		
Zymbal's Gland	(0)	(1)	(1)	(0)	(0)	(0)
Squamous Cell Carcinoma		1 (100%)				
Squamous Cell Papilloma			1 (100%)			
<b>URINARY SYSTEM</b>						
Kidney	(48)	(48)	(48)	(48)	(48)	(48)
Adenoma	1 (2%)					1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)		1 (2%)	
Histiocytic Sarcoma			2 (4%)		1 (2%)	
Leukemia Erythrocytic						1 (2%)
Lymphoma Malignant	3 (6%)	3 (6%)	4 (8%)	4 (8%)	1 (2%)	4 (8%)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)		
Urinary Bladder	(48)	(48)	(48)	(48)	(48)	(47)
Histiocytic Sarcoma		1 (2%)				
Lymphoma Malignant	1 (2%)	2 (4%)	3 (6%)	2 (4%)	1 (2%)	1 (2%)
SYSTEMIC LESIONS						
Multiple Organ	*(48)	*(48)	*(48)	*(48)	*(48)	*(48)
Histiocytic Sarcoma	1 (2%)	5 (10%)	3 (6%)		1 (2%)	1 (2%)
Leukemia Erythrocytic						1 (2%)
Leukemia Granulocytic	1 (2%)				1 (2%)	
Lymphoma Malignant	7 (15%)	4 (8%)	6 (13%)	6 (13%)	2 (4%)	9 (19%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 03039 - 02

Test Type: CHRONIC

Route: Dermal

Species/Strain: MICE/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

Triclosan

CAS Number: 3380-34-5

Date Report Requested: 12/04/2020

Time Report Requested: 13:42:33

First Dose M/F: 09/11/13 / 09/11/13

Lab: NCTR

---

B6C3F1 MICE FEMALE	Veh ctrlFemale	Tri 1.25Female	Tri 2.7 Female	Untreat Female	Tri 5.8 Female	Tri 12.5Female
--------------------	----------------	----------------	----------------	----------------	----------------	----------------

---

**Tumor Summary for Females**

Total Animals with Primary Neoplasms (b)	41	35	41	37	34	38
Total Primary Neoplasms	73	61	65	79	51	52
Total Animals with Benign Neoplasms	29	25	26	30	24	24
Total Benign Neoplasms	44	35	34	44	30	30
Total Animals with Malignant Neoplasms	25	22	24	24	21	22
Total Malignant Neoplasms	29	26	31	35	21	22
Total Animals with Metastatic Neoplasms	1	3	6	2	4	2
Total Metastatic Neoplasms	1	7	22	12	6	2
Total Animals with Malignant Neoplasms Uncertain Primary Site				1		
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors